NeuroSense Therapeutics has received the go-ahead to begin enrolling patients in the U.S. and Italy for a Phase 2b clinical trial testing PrimeC, the company’s experimental therapy for amyotrophic lateral sclerosis (ALS). The clinical trial, called PARADIGM (NCT05357950), enrolled its first participant in June. The study is…

A Phase 1/2 clinical trial is investigating the long-term safety and tolerability of BIIB105, Biogen‘s investigational treatment targeting the ataxin-2 protein, in people with amyotrophic lateral sclerosis (ALS). Called ALSpire (NCT04494256), the trial is currently recruiting adults with ALS at 12 sites in the U.S., Canada, and…

“Find the victory in this.” For nearly three decades, I’ve carried these five provocative words in my mind. Like my life, their meaning to me has evolved over time. I first heard them spoken at the funeral of a young woman, and the comment was directed to her 15-year-old son,…

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Stealth Biotherapeutics’ investigational therapy SBT-272 for the treatment of amyotrophic lateral sclerosis (ALS). Aimed at speeding the development of new treatments for rare, life-threatening diseases, orphan drug status offers regulatory support and certain financial incentives…

I must confess, whenever I’m in a crowded public place, I wear a face mask. Why? Because I’m a person living with ALS and doing everything I can to keep my immune system in tiptop shape. Plus, being the only person wearing a mask doesn’t bother me. In fact,…

We had another close call last week. I was out mowing the fields while a nursing assistant was caring for my husband, Todd. She was one of his first caregivers after he lost his ability to walk and bathe himself due to ALS. At the time, Todd still…

A cholesterol-related protein, called apolipoprotein A1 (ApoA1), can prevent the death of endothelial cells — those lining blood vessel walls — in a cell model of amyotrophic lateral sclerosis (ALS), a recent lab study shows. According to researchers, these results “show promise for ApoA1 as a therapeutic agent to…

The U.S. Food and Drug Administration (FDA) is extending by three months its review of tofersen, Biogen’s investigational treatment for forms of amyotrophic lateral sclerosis (ALS) caused by mutations in the SOD1 gene. Earlier this summer, the FDA granted the application priority review, with a decision expected no…

I’m writing this column on a tough and emotional day — the anniversary of the 2018 ALS diagnosis for my late husband, Jeff. For the day I might have planned, I’d be hiking up Old Rag Mountain in Virginia, perhaps sharing the pretty view on social media,…

Helixmith has unveiled its new multi-approach program called DART — Defeating ALS through Regenerative Therapeutics — to develop new therapies for amyotrophic lateral sclerosis (ALS). Company CEO Sunyoung Kim presented the program in person and virtually at the 2022 Cell & Gene Meeting on the Mesa, Oct. 11–13.